Abstract: Abstract: Hepatitis B virus (HBV) infection represents a major public health problem worldwide, and is accountable for chronic kidney disease (CKD). There is a difference in drug selection and dosing of antiviral therapy in CKD patients at different stages of the renal conditions. This review briefly describes the correlation between HBV infection and CKD, and focuses on the selection and dose adjustment of antiviral drugs in patients with HBV infection concomitant with renal disease, as well as the measures to optimize treatment strategies in special cases such as virological breakthrough or persistent low level viremia (LLV).

Key words: Hepatitis B virus, Chronic kidney disease, Kidney transplantation, Antiviral therapy, Research progress